BioSpace News Archive

Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos board of directors. “Natalie’s extensive background in company-building and commercial readiness makes her an exceptional addition to our board and will provide

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (“VistaGen”), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the closing of its $100 million underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per s

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company’s President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 , at 10:00 AM ET . A live webcast of the presentation will be posted under t

The Six-Month Contest Asked Global Innovators Between the Ages of 15-24 to Help Amid the Pandemic By Creating Face Mask Designs That Overcome Common Barriers to Use

Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has closed the transaction with CAIAC Fund Management AG for the Companys remaining holdings in its Polish subsidiary, Helix Immuno-Oncology S.A.

Zenith Capital Corp. (“Zenith” or the “Company”) announces that, at its annual and special meeting of shareholders held earlier today, Zenith shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated November 9, 2020 (the Information Circular), which is available on SEDAR at www.sedar.com, and on the Zenith website at www.zenithepigenetics.com . A webcast archive of the executive pres

Resverlogix Corp. (“Resverlogix”, or the “Corporation”) (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected six (6) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows: Votes For Votes Withheld

Met primary endpoint with robust statistical significance Showed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical significance Showed statistically significant onset of action as early as week 2 Had a good safety and tolerability profile throughout the study Topline data confirm positive results from prior Phase IIa study in adults and Phase III studies of SPN-812 in children and adolescents

Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders that arise inside and outside of the brain, announced today the pricing of its initial public offering of 1,800,000 shares of common stock at a public offering price of $10.00 per sha

MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that the Company has agreed to settle an amount of $65,000 owing to a professional advisor, subject to all relevant consents and approvals, by issuing 500,000 common shares to the vendor, at a price of $0.13 per share. Regulatory and other consents will include acceptance from the TSX Venture Exchange. About MedX MedX, headquartered in Mississauga, Ontar